CXCL8 and Miyoshi myopathy: After chemotherapy, serum CXCL8 levels decrease [47,57], while higher blood levels of CXCL8 are associated with a poorer prognosis [59,63,77], indicating that systemic CXCL8 production is linked to the impact of MM.